7:00 am Check-In & Coffee
8:00 am Opening Remarks
Revitalizing Progress of Allogeneic Approaches by Managing Investor Expectations & Demonstrating Key Clinical Data
8:10 am Industry Leaders’ Fireside Chat: Achieving Allogeneic Product Success by Aligning Innovation with Investor Expectations
Synopsis
An interactive panel discussion from the industry leaders of the field to set the scene on the allogeneic cell therapy space.
Ask your questions live to understand the expert’s thoughts on key topics including:
- Evaluating key success factors for allogeneic therapies and how they differ from autologous approaches
- Discussing the role of clinical trial outcomes in shaping investor confidence and the future of allogeneic products
- Discussing how to best communicate and showcase positive allogeneic therapy results
- Sharing the latest advancements in the space and how that will shape the future of allogeneic therapies
9:00 am Session Reserved for ScaleReady
9:30 am Unleashing the Promise of Cell Therapy for Cancer & Autoimmune Diseases
Synopsis
- Highlighting how Atara Bio is innovating next-generation CAR-Ts with the only allogeneic T-cell platform with an approved product
- Focusing on how EBV T-cell biology and novel CAR technologies can address the current limitations of autologous and other allogeneic CAR approaches
- Describing ATA3219, Atara Bio’s allogeneic CAR-T targeting CD19, for the potential treatment of SLE and NHL
10:00 am Highlighting Key Clinical Readouts in the Application of NK Cells to Haematological Malignancies to Further NK Therapy Development
Synopsis
- Discussing key successes thus far in clinic of Senti-202 in AML
- Sharing lessons learned and next steps
10:30 am Morning Break & Speed Networking
Synopsis
As the allogeneic community is reunited, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don’t forget to enjoy some refreshments before we split off into the two different tracks: Preclinical and Manufacturing & Process Development
Preclinical
Highlighting Key Factors in the Design of Allogeneic Products to Minimize Adverse Effects of Allotransplantation
11:30 am Developing Progenitor T-Cell Therapy to Maintain Effective & Diverse TCRs while Ensuring Safety
Synopsis
- Producing T-cell progenitors (ProTcell) with a feeder cell-free manufacturing process designed to generate clinical batches
- Infusing ProTcells that get educated and develop in the host thymus to participate in immune response without generating GvHD
- Characterizing ProTcells and T-cells generated after further maturation in artificial thymic organoids or in vivo
Using Cell Engagers to Enhance Cell Activity Endogenously & in Combination with Allogeneic Treatment
12:00 pm Exploring the Clinical Applications of Multi-Specific NK/T-Cell Engagers to Maximize Target Cell Efficacy
Synopsis
- Discussing the rationale for NK/T-cell engagers
- Diving into the anti-tumor efficacy of T-cell engagers alone and in combination with CAR-T
- Developing next gen NK/T-cell engagers for autoimmune disease
Manufacturing & Process Development
Leveraging Automation to Reduce Cost of Goods & Error in the Process
11:30 am Unlocking Closed Manufacturing to Boost Compliance & Minimize Contamination
Synopsis
- Explore the critical requirements for implementing closed manufacturing systems to enhance product integrity and reduce contamination risks
- Understand the feasibility of closed manufacturing processes, including technological advancements and operational considerations in the transition
12:00 pm Panel Discussion: Understanding When & How to Implement Automation into the Process for a Seamless Transition into Automated Manufacturing
Synopsis
- Analyze the key factors that determine the optimal timing for integrating automation into manufacturing processes, focusing on efficiency, scalability, and cost-effectiveness
- Explore different automation technologies available for allogeneic cell manufacturing
- Discuss best practices for implementing automation, including staff training, system integration, and ongoing maintenance
12:30 pm Lunch Break & Networking
Achieving Reliable & Effective Genetic Engineering to Transform Allogeneic Cells
1:30 pm How to Listen to Cells: Secretomics for Cutting-Edge Insight into Cell Function in Cancer & Immune Disorders
Synopsis
- Leveraging single cell secretomics to gain a deeper understanding of cell behaviour
- Using secretomics at mass scale in target discovery and validation, quality assurance of cells, and patient stratification
2:00 pm Leveraging NGS for Accurate Characterization of Cell Drug Products
Synopsis
- Highlighting the role of NGS in verifying the accuracy of vector sequences and preventing mutation issues
- Emphasizing the importance of NGS in ensuring the safety and efficacy of cell therapy products by checking the accuracy of CAR sequences
Refining Processes for Scalable & High-Quality Allogeneic Production
1:30 pm Elevating Starting Material Quality & Purification for Optimal Cell Yields
Synopsis
- Identify strategies for selecting and enriching high-quality starting materials to improve cell viability and therapeutic potential
- Explore advanced purification techniques that minimize contaminants while preserving target cell integrity
2:00 pm Discussing Process Optimization for iPSC-Derived NK Cells & Diving into Cryopreservation Strategies
Synopsis
- Sharing Shoreline Biosciences’ transition from academic processes to commercially applicable processes
- Refining downstream processing strategies for optimal product performance
2:30 pm Afternoon Break & Poster Session
Sharing our Current Understanding of Allogeneic Therapies Beyond Haem Malignancies to Harness the Full Potential of Universal Cell Therapies
3:30 pm Developing Allo-CAR-Ts Against Solid Tumors & Autoimmune Indications
Synopsis
- Discussing current clinical programs in solid tumors and several autoimmune conditions
- Leveraging armoring technologies to breach into solid tumors
4:00 pm Using Neural Stem Cell Delivered Oncolytic Viruses for the Treatment of Glioma & Ovarian Cancer
Synopsis
- Discussing the unique approach of using tumor-tropic NSCs as delivery vehicles of oncolytic viruses
- Discuss current multi-dose, multi-site glioma clinical trial and planned 2026 ovarian cancer clinical trials using this approach
- Manufacturing overview